[go: up one dir, main page]

YU47892A - Postupak za pravljenje rformulacije tablete - Google Patents

Postupak za pravljenje rformulacije tablete

Info

Publication number
YU47892A
YU47892A YU47892A YU47892A YU47892A YU 47892 A YU47892 A YU 47892A YU 47892 A YU47892 A YU 47892A YU 47892 A YU47892 A YU 47892A YU 47892 A YU47892 A YU 47892A
Authority
YU
Yugoslavia
Prior art keywords
rformulation
procedure
making tablet
making
tablet
Prior art date
Application number
YU47892A
Other languages
English (en)
Other versions
YU49069B (sh
Inventor
L.C. Martin
J.D. Mromero
Original Assignee
Laboratorios Beecham Sa.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Beecham Sa. filed Critical Laboratorios Beecham Sa.
Publication of YU47892A publication Critical patent/YU47892A/sh
Publication of YU49069B publication Critical patent/YU49069B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

POSTUPAK ZA PRAVLJENJE RFORMULACIJE TABLETE, postupak za pravljenje formulacije tablete koja se sastoji od granula koje imaju strukturu koja obuzh
YU47892A 1991-05-08 1992-05-06 Postupak za pravljenje formulacije tablete YU49069B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919109862A GB9109862D0 (en) 1991-05-08 1991-05-08 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
YU47892A true YU47892A (sh) 1994-12-28
YU49069B YU49069B (sh) 2003-08-29

Family

ID=10694582

Family Applications (1)

Application Number Title Priority Date Filing Date
YU47892A YU49069B (sh) 1991-05-08 1992-05-06 Postupak za pravljenje formulacije tablete

Country Status (33)

Country Link
US (3) US6110497A (sh)
EP (3) EP0787487B1 (sh)
JP (1) JPH06507396A (sh)
KR (1) KR100228450B1 (sh)
CN (2) CN1056277C (sh)
AP (1) AP328A (sh)
AT (3) ATE252900T1 (sh)
AU (1) AU659836B2 (sh)
BR (1) BR9205948A (sh)
CA (1) CA2102630C (sh)
CZ (1) CZ291795B6 (sh)
DE (3) DE69231965T2 (sh)
DK (1) DK0585252T3 (sh)
ES (3) ES2161690T3 (sh)
FI (1) FI110354B (sh)
GB (1) GB9109862D0 (sh)
GR (1) GR3036937T3 (sh)
HU (1) HU219348B (sh)
IE (1) IE921472A1 (sh)
IL (1) IL101795A (sh)
MA (1) MA22522A1 (sh)
MX (1) MX9202118A (sh)
MY (1) MY111879A (sh)
NO (1) NO312224B1 (sh)
NZ (1) NZ242625A (sh)
PT (1) PT100458B (sh)
SA (1) SA92130069B1 (sh)
SG (1) SG55163A1 (sh)
SK (1) SK282333B6 (sh)
TW (1) TW240172B (sh)
WO (1) WO1992019227A2 (sh)
YU (1) YU49069B (sh)
ZA (1) ZA923272B (sh)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
JPH11510811A (ja) * 1995-08-12 1999-09-21 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 医薬処方
NZ337247A (en) 1995-09-07 2001-05-25 Smithkline Beecham Corp Pharmaceutical tablet formulation comprising 875mg amoxycillin
KR20040058360A (ko) * 1996-02-29 2004-07-03 후지사와 야꾸힝 고교 가부시키가이샤 합성 감미료
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
AT407701B (de) * 1996-08-12 2001-05-25 Biochemie Gmbh Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
US6893664B1 (en) 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
GB9616536D0 (en) 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
WO1998034598A2 (en) * 1997-02-07 1998-08-13 Gist-Brocades B.V. Homogeneous granulated formulations for dose sipping technology
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
ID23673A (id) * 1997-02-14 2000-05-11 Smithkline Beecham Lab Pharma Formulasi farmasi yang terdiri dari amoksicilin dan klavulanat
WO1999011261A1 (en) * 1997-08-29 1999-03-11 Dsm N.V. Granules free of excipients
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
WO2000025751A2 (en) * 1998-10-30 2000-05-11 Fuisz International Ltd. Improved amoxycillin and clavulanate composition
US6177421B1 (en) 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
US6979735B1 (en) 1999-04-01 2005-12-27 Dsm N.V. Agglomerates by crystallization
IE20000271A1 (en) * 1999-04-13 2001-04-04 Beecham Pharm Pte Ltd Pharmaceutical Formulations of Amoxycillin and Potassium Clavulanate
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US20020006433A1 (en) * 1999-04-29 2002-01-17 Nigel P. Davidson Pharmaceutical formulations
GB9930578D0 (en) * 1999-12-23 2000-02-16 Smithkline Beecham Plc Pharmaceutical formulations
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
DE60108154T2 (de) * 2000-10-20 2005-12-22 Sandoz Ag Pharmazeutische Zubereitungen enthaltend Clavulansäure
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
AT412344B (de) * 2001-04-12 2005-01-25 Sandoz Ag Hydrophobisierte teilchen von k-clavulanat
AT413983B (de) * 2001-04-12 2006-08-15 Sandoz Ag K-clavulanat in der form eines granulates
WO2003086343A2 (en) * 2002-04-05 2003-10-23 Cadila Healthcare Limited Fast disintegrating oral dosage forms
KR20050062514A (ko) * 2002-07-16 2005-06-23 랜박시 래보러터리스 리미티드 경구 투여용 분산성 정제
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005009368A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
AU2004273830B2 (en) * 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1686963A1 (en) * 2003-10-27 2006-08-09 PSivida Inc. Suspension delivery system for the sustained and controlled local release of pharmaceuticals
JP2007517039A (ja) * 2003-12-24 2007-06-28 アドバンシス ファーマスーティカル コーポレイション 変性放出製剤の吸収増強
US8715734B2 (en) * 2004-02-24 2014-05-06 Sandoz Ag Amoxicilline instant granulate
WO2005115347A1 (en) * 2004-05-31 2005-12-08 Sam-A Pharmaceuticals Co., Ltd. Dispersible tablet comprising beta lactam antibiotics and process for preparing the same
EP1771158A4 (en) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2006222061B2 (en) 2005-03-03 2011-04-28 Janssen Pharmaceutica N.V. Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
DE602006016244D1 (de) 2005-03-08 2010-09-30 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
WO2007058397A1 (en) * 2005-11-17 2007-05-24 Gl Pharmtech Corp. A dispersible tablet comprising the mixture of amoxicillin and clavulanic acid or its salts and processes for preparing the same
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
FI20070521A7 (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
US8951562B2 (en) * 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
PL2487161T5 (pl) 2007-02-23 2024-09-09 Gilead Sciences, Inc. <div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
US20090270358A1 (en) 2007-10-26 2009-10-29 Rexahn Pharmaceuticals, Inc. Pharmaceutical formulation of clavulanic acid
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PL2296633T3 (pl) 2008-05-02 2016-03-31 Gilead Sciences Inc Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
WO2009135946A1 (en) 2008-05-09 2009-11-12 Atacama Labs Oy Method and apparatus for dry granulation
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AR074689A1 (es) * 2008-12-19 2011-02-02 Solvay Pharm Bv Formulaciones farmaceuticas de desintegracion rapida pre-compactadas de compuestos con baja biodisponibilidad oral. proceso de preparacion
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012009857A8 (pt) 2009-10-26 2023-04-11 Merck Sharp & Dohme Composições farmacêuticas sólidas contendo um inibidor de integrase
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
MX2012012438A (es) * 2010-05-05 2012-11-29 Boehringer Ingelheim Int Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
KR20220025926A (ko) 2010-06-24 2022-03-03 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103781788B (zh) 2011-07-15 2016-08-17 勃林格殷格翰国际有限公司 经取代的喹唑啉、其制备及其在药物组合物中的用途
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014023710A1 (en) * 2012-08-07 2014-02-13 Sandoz Ag UNCOATED TABLET COMPRISING GRANULES INCLUDING A β-LACTAM ANTIBIOTIC AND HIGHLY DISPERSED SILICONE DIOXIDE
JP2014079286A (ja) * 2012-10-12 2014-05-08 Hiroaki Koga 抗菌剤入容器
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
EP3518924B1 (en) 2016-09-30 2022-08-10 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN110191704A (zh) * 2016-10-24 2019-08-30 爱尔兰詹森科学公司 可分散组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1552416A (en) * 1975-08-12 1979-09-12 Beecham Group Ltd Pharmaceutical compositions
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
DE3134591A1 (de) * 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US5275823A (en) * 1989-04-27 1994-01-04 Smith Kline & French Laboratories Ltd. Pharmaceutical compositions
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
US5861172A (en) * 1991-05-08 1999-01-19 Laboratorios Beecham Sa Pharmaceutical formulations of compacted granulates of β-lactam antibiotics

Also Published As

Publication number Publication date
ES2161690T3 (es) 2001-12-16
ZA923272B (en) 1993-03-31
HUT67020A (en) 1995-01-30
NO312224B1 (no) 2002-04-15
DE69233239T2 (de) 2004-08-19
WO1992019227A2 (en) 1992-11-12
HU9303143D0 (en) 1994-01-28
SG55163A1 (en) 1998-12-21
CZ291795B6 (cs) 2003-05-14
CN1056277C (zh) 2000-09-13
ES2235210T3 (es) 2005-07-01
DK0585252T3 (da) 2001-11-12
EP0787487B1 (en) 2004-12-22
DE69233464T2 (de) 2006-04-13
SK112793A3 (en) 1994-06-08
PT100458B (pt) 1999-07-30
NZ242625A (en) 1994-08-26
DE69233464D1 (de) 2005-01-27
TW240172B (sh) 1995-02-11
GB9109862D0 (en) 1991-07-03
IL101795A0 (en) 1992-12-30
ATE203400T1 (de) 2001-08-15
DE69231965T2 (de) 2002-04-04
US6352720B1 (en) 2002-03-05
BR9205948A (pt) 1994-11-08
JPH06507396A (ja) 1994-08-25
PT100458A (pt) 1993-08-31
US6110497A (en) 2000-08-29
ES2212034T3 (es) 2004-07-16
DE69231965D1 (de) 2001-08-30
EP0585252A1 (en) 1994-03-09
NO934009D0 (no) 1993-11-05
ATE252900T1 (de) 2003-11-15
US6544558B2 (en) 2003-04-08
EP0787487A1 (en) 1997-08-06
ATE285227T1 (de) 2005-01-15
CN1155370C (zh) 2004-06-30
CN1067577A (zh) 1993-01-06
AP9200382A0 (en) 1992-07-31
CZ237993A3 (en) 1994-03-16
WO1992019227A3 (en) 1992-12-23
IE921472A1 (en) 1992-11-18
NO934009L (no) 1993-11-05
AP328A (en) 1994-03-23
MX9202118A (es) 1993-03-01
SK282333B6 (sk) 2002-01-07
KR100228450B1 (ko) 1999-11-01
EP0783889B1 (en) 2003-10-29
SA92130069B1 (ar) 2005-04-16
DE69233239D1 (de) 2003-12-04
CA2102630A1 (en) 1992-11-09
CA2102630C (en) 2004-01-13
EP0783889A1 (en) 1997-07-16
MA22522A1 (fr) 1992-12-31
MY111879A (en) 2001-02-28
FI934914L (fi) 1993-11-05
AU1649892A (en) 1992-12-21
GR3036937T3 (en) 2002-01-31
FI934914A0 (fi) 1993-11-05
EP0585252B1 (en) 2001-07-25
CN1265882A (zh) 2000-09-13
YU49069B (sh) 2003-08-29
HU219348B (en) 2001-03-28
AU659836B2 (en) 1995-06-01
FI110354B (fi) 2002-12-31
US20020064562A1 (en) 2002-05-30
IL101795A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
YU47892A (sh) Postupak za pravljenje rformulacije tablete
ZA924285B (en) Method for production of granules
IL97890A0 (en) Production of sucrose-6-esters
HU9201929D0 (en) Process for the production of imidazo-diazepines
EP0493916A3 (en) Production of compounds
IL98015A0 (en) Production of preshrunk denim
IL55086A0 (en) Bicyclic thiadiaza compounds,their production and pharmaceutical compositions containing them
HU910151D0 (en) Process for the production of substituted 2-chloride-pyridines
JPS574954A (en) Manufacture of fluorene derivative
NZ239813A (en) Fungicidally active compounds, their methods of production and compositions containing them
NO180450C (no) Farmasöytiske formuleringer og fremgangsmåte for fremstilling av form II diritromycin
ZA785489B (en) Process for the manufacture of biologically active granules
ZA918128B (en) Process for production of polyfluoroolefins.
ZA912389B (en) Selective production of aminoethylethanolamine
HU913518D0 (en) Substituted aminoacid-amide-derivatives and process for the production of the compounds, and the pesticides containing them
GB9022071D0 (en) Production of hydroxyletones
JPS57145659A (en) Production of tablet
GB9123254D0 (en) Production of solid fuels
JPS5742968A (en) Production of knitted article
ZA902171B (en) Production of modified pe40
HU9201547D0 (en) Stereo- and enantioselective process for the production of furanomethanoles
GB9104706D0 (en) Production of rivet-nuts
JPS5697449A (en) Production of sanitary article
JPS5777358A (en) Production of knitted briefs material
ZA918604B (en) Prevention of toxin production using absorbent products.